PlumX Metrics
Embed PlumX Metrics

Ex Vivo Patient-Derived Explant Model for Neurofibromatosis Type 1–Related Cutaneous Neurofibromas

Journal of Investigative Dermatology, ISSN: 0022-202X, Vol: 144, Issue: 9, Page: 2052-2065.e8
2024
  • 0
    Citations
  • 0
    Usage
  • 2
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Captures
    2
  • Mentions
    1
    • News Mentions
      1
      • 1

Most Recent News

New Neurofibromatosis Type 1 Data Have Been Reported by Researchers at Van Andel Research Institute (Ex Vivo Patient-derived Explant Model for Neurofibromatosis Type 1-related Cutaneous Neurofibromas)

2024 SEP 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Daily News -- New research on Nervous System

Article Description

Cutaneous neurofibromas (CNFs) are benign tumors that occur in the dermis of individuals with the inherited tumor predisposition disorder, neurofibromatosis type 1. CNFs cause disfigurement, pain, burning, and itching, resulting in substantially reduced QOL in patients with neurofibromatosis type 1. CNFs are benign tumors that exhibit cellular and molecular heterogeneity, making it difficult to develop tractable in vitro or in vivo models. As a result, CNF research and drug discovery efforts have been limited. To address this need, we developed a reproducible patient-derived explant (PDE) ex vivo culture model using CNF tumors from patients with neurofibromatosis type 1. CNF PDEs remain viable in culture for over 9 days and recapitulate the cellular composition and molecular signaling of CNFs. Using CNF PDEs as a model system, we found that proliferation was associated with increased T-cell infiltration. Furthermore, we identified a pattern of reciprocal inflammatory signaling in CNF PDEs in which tumors rely on prostaglandin or leukotriene-mediated signaling pathways. As proof of principle, we show that ex vivo glucocorticoid treatment reduced the expression of proinflammatory genes, confirming that CNF PDEs are a useful model for both mechanistic studies and preclinical drug testing.

Bibliographic Details

Grit, Jamie L; Turner, Lisa; Essenburg, Curt J; Gallik, Kristin L; Dischinger, Patrick S; Shurlow, Nathan D; Pate, Matthew J; Graveel, Carrie R; Steensma, Matthew R

Elsevier BV

Biochemistry, Genetics and Molecular Biology; Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know